NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Ilovetech, Good points. Country budget constraints are legitimate realities.

Say the DCVax gross margin % is 70% and Eden (automation) saves $15K in manufacturing cost. That translates into a $50K lower selling price or a savings to the UK's NHS, while NWBO gets to maintain its profit % and maybe faster expansion into markets, a win-win.

It is a matter of when, ie the UK being nimble to expedite approvals and expansions, but if it can, I see these trade-offs:

- more DCVax-L (better, cheaper) means less other more expensive drugs
- expedite Eden approval means earlier cost savings for NICE/NHS
- e.g. label expansion to stage agnostic (same biological mechanism, include grade 3 gliomas)
- e.g. label across tumor types (DCs are agnostic)

Interests are aligned. The UK will want DCVax-L, a breakthrough cancer therapy, to succeed big time even though it is a USA company. Sawston's expansion and success in the UK creates high skill jobs and continued investment. A profitable UK operations means UK taxable income grows and positions the UK as a global leader in life sciences and will attract more biotech investment, partnerships, and talent to their shores. Financial gain and soft power gain.